Vaxxinity, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of debt issuance costs
Amortization of discount on short-term investments
Change in fair value of Series A preferred stock
Stock-based compensation expense
Non-cash consulting expense
Non-cash loss on disposal
Change in fair value of convertible notes
Change in fair value of warrant liability
Change in fair value of simple agreement for future equity
Change in operating assets and liabilities:
Amounts due from related parties
Accounts receivable
Prepaid expenses and other current assets
Deferred offering costs
Accounts payable
Amounts due to related parties
Accounts payable
Nonrelated Party
Related Party
Accrued expenses and other current liabilities
Other long-term liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchase of short-term investments
Redemption of short-term investments
Purchase of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from initial public offering, net of offering expenses of $13,913
Proceeds from issuance of convertible notes payable with related parties
Proceeds from issuance of convertible note payable
Repayment of convertible notes
Repayment of notes payable
Additional SAFEs
Payment of debt issuance costs for related party convertible notes
Repayment from Paycheck Protection Program
Repayments of note payable with related party
Proceeds from issuance of Series B convertible preferred stock, net of issuances costs
Series Seed-1 Stock
Series Seed-2 Stock
Series B Preferred Stock
Series A-1 Stock
Common Class A
SAFEs
Total proceeds from issuance of Series B convertible preferred stock, net of issuances costs
Payment for convertible preferred stock issuance costs
Proceeds from exercise of stock options
Net cash used in financing activities
Change in cash, cash equivalents, and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Less restricted cash
Cash and cash equivalents
Supplemental Disclosure
Cash paid for interest
Noncash Financing Activities
Acquisition of airplane through issuance of note payable
Fair value of warrants issued in connection with preferred stock issuance
Reitrement Of Treasury Shares
Retirement Of Treasury Shares
Fair Value of Restricted Stock, Vested
Conversion of amounts due to related party into note payable to related party
SAFEs
Related Party Into Note Payable
Series A and Series B to Class A Common Stock
Series Seed, Series Seed-1, Series Seed-2, Series A-1 and Series A-2 for Series A
Convertible Notes Payable to Series A Preferred
Notes into Series A Preferred
Warrant to Series A Preferred
Warrant to Class A Common Stock
SAFE to Series A2 Preferred
SAFE to Seed2 Preferred
Warrant to Series A1 Preferred
Total conversion of amounts due to related party into note payable to related party

Comments